同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02410 同源康医药-B

未开盘 08-14 16:08:36

6.725

-0.125

-1.82%

最高7.125	最低6.680	成交量177.30万
今开6.765	昨收6.850	日振幅6.50%
总市值25.56亿	流通市值25.25亿	总股本3.80亿
成交额1,206万	换手率0.47%	流通股本3.75亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02410","market":"HK","secType":"STK","nameCN":"同源康医药-B","latestPrice":6.725,"timestamp":1786694916006,"preClose":6.85,"halted":0,"volume":1773000,"delay":0,"changeRate":-0.018248175182481754,"floatShares":375457818,"shares":380065818,"eps":-0.8,"marketStatus":"未开盘","change":-0.125,"latestTime":"08-14 16:08:36","open":6.765,"high":7.125,"low":6.68,"amount":12055692,"amplitude":0.064964,"askPrice":6.8,"askSize":1000,"bidPrice":6.725,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-0.890654,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1786930200000},"marketStatusCode":0,"adr":0,"listingDate":1724083200000,"exchange":"SEHK","adjPreClose":6.85,"openAndCloseTimeList":[[1786671000000,1786680000000],[1786683600000,1786694400000]],"volumeRatio":0.4775886219028771,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02410","defaultTab":"news","newsList":[{"id":"2658369969","title":"创新药概念继续走强 金斯瑞生物科技（01548）涨6.87% 机构指中国创新药全球地位持续提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2658369969","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658369969?lang=zh_cn&edition=full","pubTime":"2026-08-11 11:15","pubTimestamp":1786418137,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念持续走强，截至发稿，金斯瑞生物科技 涨6.87%，再鼎医药涨5.51%，同源康医药-B涨4.81%，晶泰控股涨3.94%，药明合联涨3.92%，翰森制药涨3.76%，亚盛医药涨3.63%，百济神州涨3.38%，药明康德涨3.03%，诺诚健华涨2.83%，石药集团涨2.78%。国元国际证券亦表示，出海交易量价齐升，中国创新药全球地位持续提升。中国创新药出海持续超预期，上半年997亿美元的交易总额和全球TOP10中独占8席的成绩，充分验证了中国创新药资产的全球竞争力。","market":"hk","thumbnail":"https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250110/MmQ2MzI0NzdkYTM0MjU4ODU0NDE5OWM2MjQ0NmE1ZTExMDg1Mjk2Mjc3MDg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987912","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU2488822045.USD","BK1521","LU0072913022.USD","LU1226288170.HKD","LU2242644610.SGD","LU1993786604.SGD","LU1152091168.USD","01093","03692","LNGR","LU0326950275.SGD","LU1226287792.SGD","LU0315179316.USD","06855","BK1588","BK1617","LU0880133367.SGD","HK0000320223.HKD","IE00B5MMRT66.SGD","09969","IBBQ","LU1813983027.USD","02410","06978","02268","BK1161","BK1515","LU1303224171.USD","LU1951186391.HKD","02228","06160","BK1583","159992","IE00BZ08YT58.USD","IE00B031HY20.USD","LU1226287875.USD","MEDX","IE00B543WZ88.USD","HK0000306685.HKD","LU2125910500.SGD","IE00BZ08YS42.EUR","09688","02359","IE00BZ08YR35.GBP","BK1576","LU2328871848.SGD","KURE","BK1500","01548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104587482","title":"同源康医药-B（02410）将于8月17日召开董事会审议2026年中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1104587482","media":"公告速递","labels":["conferences","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1104587482?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:22","pubTimestamp":1785921722,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司（股票代码：02410，股票简称：同源康医药-B）8月5日公告称，公司董事会会议将于2026年8月17日（星期一）举行。届时，董事会将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并讨论是否派发中期股息（如有）。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120386864","title":"同源康医药-B更新7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1120386864","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120386864?lang=zh_cn&edition=full","pubTime":"2026-08-05 17:11","pubTimestamp":1785921109,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司（同源康医药-B，股票代码：02410）于2026年8月5日发布截至2026年7月31日的股份变动月报表。报告显示，公司期末注册股本为人民币380,065,818元，各类已发行普通股合计380,065,818股，面值每股人民币1元，库藏股数量为0股。\n报告期内，公司无新增发行、购回、注销或库藏股变动，股本结构保持稳定。公司亦表示，其已满足香港联交所对于上市发行人最低公眾持股量不低于该类别股份总数的25%之规定。根据公告信息，本次月报由执行董事、董事长兼总裁吴豫生签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654972091","title":"同源康医药-B午后涨超5% 齐鲁制药获TY-9591独家商业化授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2654972091","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654972091?lang=zh_cn&edition=full","pubTime":"2026-07-27 13:12","pubTimestamp":1785129120,"startTime":"0","endTime":"0","summary":"　　同源康医药-B盘中涨超6%，截至发稿，股价上涨5.39%，现报7.23港元，成交额1757.17万港元。　　齐鲁制药获同源康医药肺癌靶向创新药TY-9591独家商业化授权，齐鲁制药还将对同源康医药进行股权投资。　　公开资料显示，TY-9591是同源康医药自主研发的新一代高选择性不可逆EGFR-TKI，也是国内差异化优势突出的肺癌靶向新药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-07-27/doc-inikfnpf3106086.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1191","BK1161","09939","02410","01477","BK1574","159938","BK1515","TY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654109998","title":"港股异动 | 同源康医药-B(02410.HK)午前涨超6% 齐鲁制药获TY-9591独家商业化授权 拟股权投资同源康","url":"https://stock-news.laohu8.com/highlight/detail?id=2654109998","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654109998?lang=zh_cn&edition=full","pubTime":"2026-07-27 11:56","pubTimestamp":1785124614,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","BK1161","02410","01477","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653698237","title":"同源康医药-B(02410)对四川汇宇制药股份有限公司提起法律程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2653698237","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653698237?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:56","pubTimestamp":1784732193,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司最近已向长兴县人民法院提交一宗案件，对四川汇宇制药股份有限公司(汇宇)提起法律程序，寻求以下司法确认：一份声称与汇宇订立的TY-9591相关合作协议及经销协议并未成立且属无效。本公司亦收到内江市市中区人民法院就汇宇就据称由本公司与汇宇订立的同一合作协议、经销协议及相关文件所发出的案件受理通知书。两宗案件均已立案，惟尚未在法院审理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471138.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1515","01477","09939","159938","BK1191","BK1574","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105550769","title":"同源康医药-B就TY-9591合作协议纠纷启动法律程序","url":"https://stock-news.laohu8.com/highlight/detail?id=1105550769","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105550769?lang=zh_cn&edition=full","pubTime":"2026-07-22 22:55","pubTimestamp":1784732129,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司7月22日发布公告称，公司已在长兴县人民法院对四川汇宇制药股份有限公司提起诉讼，要求法院确认双方所谓的TY-9591合作协议及经销协议“不成立且无效”。\\n\\n同源康医药-B同时透露，其亦收到内江市市中区人民法院就同一合作协议、经销协议及相关文件立案的受理通知书。两宗案件均已立案，但均尚未开庭审理。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653778219","title":"港股异动 | 同源康医药-B(02410.HK)高开近15% 与齐鲁制药达成战略合作加速TY-9591商业化","url":"https://stock-news.laohu8.com/highlight/detail?id=2653778219","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653778219?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:24","pubTimestamp":1784683457,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","09939","02410","01477","BK1161","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653827429","title":"同源康医药-B(02410.HK)携手齐鲁推进新药物TY-9591的开发、生产与商业化 后者斥资4亿元战略入股","url":"https://stock-news.laohu8.com/highlight/detail?id=2653827429","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653827429?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:28","pubTimestamp":1784633304,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","BK1515","09939","BK1574","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1113169040","title":"同源康医药-B（02410）拟获齐鲁制药7亿元人民币首付款并以配股融资4亿元人民币","url":"https://stock-news.laohu8.com/highlight/detail?id=1113169040","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1113169040?lang=zh_cn&edition=full","pubTime":"2026-07-21 19:25","pubTimestamp":1784633151,"startTime":"0","endTime":"0","summary":"2026年7月21日，浙江同源康医药股份有限公司公告称，公司已于当日收市后与齐鲁制药（海南）有限公司及其指定关联方签署多份合作文件，并拟向齐鲁全资子公司Anchor International Limited定向增发H股。－ 同源康医药-B将获得3亿元人民币现金首付款，并可在TY-9591取得监管批准及适应症扩展后，获得最高20.6亿元人民币里程碑付款。－ 齐鲁或其关联方将同时通过认购H股向同源康医药-B支付约4亿元人民币，对应总首付款达7亿元人民币。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2653226476","title":"港股异动 | 同源康医药-B(02410)午后涨超15% 艾多替尼头对头击败奥希替尼 预计将于三季度上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2653226476","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653226476?lang=zh_cn&edition=full","pubTime":"2026-07-21 13:43","pubTimestamp":1784612607,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B午后涨超15%，截至发稿，涨12.37%，报8.54港元，成交额5376.03万港元。消息面上，2026年ASCO大会上，同源康医药以LBA口头报告的形式，公布了艾多替尼用于EGFR突变非小细胞肺癌脑转移患者一线治疗的ESAONA研究期中分析结果。国海证券指出，艾多替尼在NSCLC脑转移患者中头对头击败奥希替尼，预计将于2026年第三季度上市。预计未来三年公司营收主要由TY9591贡献。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1470236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","VXUS","BK1574","159938","BK4585","BK4588","02410","IPOS","BK1515","09939","KCAI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653223961","title":"港股同源康医药-B涨幅扩大至14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653223961","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653223961?lang=zh_cn&edition=full","pubTime":"2026-07-21 11:46","pubTimestamp":1784605567,"startTime":"0","endTime":"0","summary":"【港股同源康医药-B涨幅扩大至14%】7月21日，港股同源康医药-B涨幅扩大至14%，报8.73港元/股，总市值33亿港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607213815173261.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607213815173261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["159938","BK4588","VXUS","BK4585","KCAI","02410","BK1161","09939","BK1515","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1172333869","title":"同源康医药-B（02410）特别决议获逾九成赞成通过发行授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1172333869","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1172333869?lang=zh_cn&edition=full","pubTime":"2026-07-15 17:01","pubTimestamp":1784106100,"startTime":"0","endTime":"0","summary":"2026年7月15日，同源康医药-B公布2026年第一次临时股东大会投票结果。会上，公司就“发行股份的发行授权”提出的特别决议案获得135,580,001票赞成，占有效表决权的93.58%；反对票4,625,576票，占3.19%；弃权票4,681,502票，占3.23%。由于赞成票比例超过三分之二，相关决议正式获股东通过。截至会议当日，公司已发行股份总数为380,065,818股。本次会议的召集、召开及表决程序均符合中国公司法及公司章程的相关规定，香港中央证券登记有限公司担任监票机构。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651125795","title":"港股异动 | 同源康医药-B(02410)涨超15% 第三代EGFR-TKITY-9591商业化在即 艾多替尼头对头击败奥希替尼","url":"https://stock-news.laohu8.com/highlight/detail?id=2651125795","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651125795?lang=zh_cn&edition=full","pubTime":"2026-07-14 10:22","pubTimestamp":1783995771,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B盘中涨超15%，截至发稿，涨12.68%，报7.82港元，成交额4935.6万港元。国海证券发布研报称，艾多替尼在NSCLC脑转移患者中头对头击败奥希替尼。第三代EGFR-TKI药物针对脑转移病灶的穿透与抑制能力仍存在短板。该行续指，公司预计第三代EGFR-TKITY-9591将于2026Q3上市。TY-9591的EGFR突变的晚期或转移性肺癌适应症，预计2026年下半年启动3期临床试验。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1467007.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","02410","VXUS","BK1161","BK4585","KCAI","159938","BK4588","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649393952","title":"港股异动 | 同源康医药-B(02410)涨超6%  艾多替尼精准布局肺癌脑转移赛道 机构料产品有望于Q3上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2649393952","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649393952?lang=zh_cn&edition=full","pubTime":"2026-07-08 11:26","pubTimestamp":1783481174,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，同源康医药-B涨超6%，截至发稿，涨5.63%，报6.76港元，成交额1109.07万港元。消息面上，此前2026年ASCO年会重磅揭晓关键临床突破，同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片，用于EGFR突变非小细胞肺癌脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要口头报告形式重磅发布。国海证券发布研报称，艾多替尼在NSCLC脑转移患者中头对头击败奥希替尼，预计将于2026Q3上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1464555.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["KCAI","IPOS","BK4588","159938","BK1161","BK1515","BK4585","09939","VXUS","BK1574","02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106148483","title":"同源康医药-B2026年6月股份变动月报：股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1106148483","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106148483?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:25","pubTimestamp":1782987933,"startTime":"0","endTime":"0","summary":"同源康医药-B于2026年7月2日披露了2026年6月股份变动月报表，内容涉及2026年6月1日至6月30日期间的股本变动及公众持股情况。公告显示，公司截至6月末的已发行普通股总数（H股）为380,065,818股，较上月无变动，库存股份为0股，注册股本维持人民币380,065,818元。公司确认满足相关上市规则规定的最低公众持股量要求，股权结构持续保持稳定。公司表示，将继续依照香港联合交易所有限公司《上市规则》及相关法律法规履行信息披露义务。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109513371","title":"同源康医药-B（02410）7月15日召开2026年首场临时股东会 拟授予发行新股授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1109513371","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109513371?lang=zh_cn&edition=full","pubTime":"2026-06-29 20:06","pubTimestamp":1782734771,"startTime":"0","endTime":"0","summary":"– 特别决议案：审议并批准“发行股份的发行动授权”，如获通过，董事会将可在法定额度内灵活进行股份发行，为公司后续融资及资本运作提供支持。– 公司股份奖励计划受托人所持1,480,500股需按上市规则放弃投票。股东可委派一名或多名代表出席并投票；会议预计不超过半个工作日，与会人员交通及住宿费用自理。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173934852","title":"同源康医药-B2026年5月股份变动月报：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1173934852","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173934852?lang=zh_cn&edition=full","pubTime":"2026-06-02 18:27","pubTimestamp":1780396022,"startTime":"0","endTime":"0","summary":"浙江同源康医药股份有限公司于2026年6月2日披露了截至2026年5月31日的股份变动月报表。公告显示，公司报告期内无新增发行或购回、注销及库存股变动，股本结构保持稳定。根据披露信息，公司的H股截至本报告期末已发行股份数量为380,065,818股，库藏股数量为0股，已发行股份总数合计380,065,818股，与上月末持平。本次公告未披露任何关于股份期权及激励计划的授出、行使或变动情况，也未出现可换股票据或其他任何新股发行协议。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02410"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640982166","title":"ASCO 2026重磅突破 | 同源康医药(02410)艾多替尼颅内客观缓解率95.5% 全面领跑EGFR肺癌脑转移一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2640982166","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640982166?lang=zh_cn&edition=full","pubTime":"2026-06-01 10:06","pubTimestamp":1780279582,"startTime":"0","endTime":"0","summary":"港股创新药企同源康医药自主研发的新一代EGFR-TKI创新药甲磺酸艾多替尼片，用于EGFR突变非小细胞肺癌脑转移患者一线治疗的关键II期ESAONA研究期中分析结果，以最新突破性摘要口头报告形式重磅发布。商业化进程加速落地，有望重塑肺癌脑转移治疗格局依托ESAONA研究的突破性阳性数据，艾多替尼已展现出疗效更优、安全性可控、差异化优势显著的核心产品力，有望成为EGFR突变肺癌脑转移患者的一线优选全新方案。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448302.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02410","BK1161","BK1515","159938","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639600214","title":"同源康医药-B(02410)：艾多替尼一线治疗晚期非小细胞肺癌脑转移的关键性研究最新成果以LBA形式于2026年ASCO年会上公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2639600214","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639600214?lang=zh_cn&edition=full","pubTime":"2026-05-31 18:18","pubTimestamp":1780222714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B 发布公告，本公司自主研发的甲磺酸艾多替尼片 对比奥希替尼一线治疗表皮生长因子受体突变非小细胞肺癌 脑转移患者关键II期ESAONA研究的期中分析结果，已于2026年美国临床肿瘤学会年会上以最新突破性摘要“LBA”口头报告形式公布。ESAONA研究是一项开放标签、多中心、随机对照的关键II期临床研究，旨在评估艾多替尼对比奥希替尼一线治疗EGFR经典突变NSCLC脑转移患者的疗效和安全性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448182.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1574","09939","02410","BK1161","159938"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0261},{"period":"1month","weight":-0.1738},{"period":"3month","weight":-0.1956},{"period":"6month","weight":-0.4746},{"period":"1year","weight":-0.6363},{"period":"ytd","weight":-0.487}],"compareEarnings":[{"period":"1week","weight":-0.0215},{"period":"1month","weight":0.0177},{"period":"3month","weight":-0.0326},{"period":"6month","weight":-0.0546},{"period":"1year","weight":-0.0158},{"period":"ytd","weight":-0.02}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"浙江同源康医药股份有限公司是一家致力于开发及商业化医药产品的中国公司。该公司专注于小分子药物开发，其主要产品包括TY-9591、TY-302和TY-2136。TY-9591是一种第三代EGFR-TKI，对EGFR突变具有抗肿瘤作用。TY-302是一种为治疗乳腺癌及前列腺癌等晚期实体瘤而开发的强效、选择性口服CDK4/6抑制剂。TY-2136b为自主研发、口服ROS1/NTRK抑制剂，用于治疗实体瘤。","exchange":"SEHK","name":"同源康医药-B","nameEN":"TYK MEDICINES-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"同源康医药-B,02410,同源康医药-B股票,同源康医药-B股票老虎,同源康医药-B股票老虎国际,同源康医药-B行情,同源康医药-B股票行情,同源康医药-B股价,同源康医药-B股市,同源康医药-B股票价格,同源康医药-B股票交易,同源康医药-B股票购买,同源康医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"同源康医药-B(02410)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供同源康医药-B(02410)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}